MetLife, Inc. MET
Verdict: Hold. Fair value $98.66 against a price of $81.77 on 6 Jan 2026, 21% above the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. GAAP Net Income exhibits extreme volatility ($6.86B in 2021, $1.58B in 2023, $4.43B in 2024) that....
Main risks
- Highly Volatile Net Income: Earnings fell from $5.28B in 2022 to $1.58B in 2023 before rebounding, indicating low predictability and high sensitivity to market or accounting factors.
- Anemic Top-Line Growth: The 3-year revenue CAGR is a sluggish 3.3%, including a contraction in 2023, pointing to a mature business struggling for meaningful expansion.
- Poor Earnings Surprise History: A 25% beat rate over the last four quarters with a 0.0% average surprise suggests management consistently fails to exceed muted market expectations, which can erode investor confidence.
- GAAP Net Income exhibits extreme volatility ($6.86B in 2021, $1.58B in 2023, $4.43B in 2024) that...
- Intense competitive environment
- GAAP Net Income exhibits extreme volatility ($6.86B in 2021, $1.58B in 2023, $4.43B in 2024) that does not reflect the stable, growing trend of Operating Cash Flow ($12.35B in 2021 to $14.60B in 2024). This massive divergence indicates that reported earnings are heavily influenced by non-cash, mark-to-market adjustments and are not a reliable indicator of the company's core operational performance.